Clinical trials with ifosfamide

The Indiana University experience

Patrick Loehrer, Stephen D. Williams, Craig R. Nichols, Lawrence Einhorn

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

At Indiana University, we began clinical trials with ifosfamide in 1981. Although our initial efforts were in a variety of tumor types, including pancreatic cancer, we have most recently focused our attention on two tumors that have historically exhibited a higher degree of chemosensitivity-testicular cancer and small cell lung cancer (SCLC). In phase II trials, ifosfamide has proven to have single-agent activity in both diseases. Coupling this data with preclinical observations of synergy with cisplatin and etoposide, we began trials of ifosfamide plus cisplatin with either vinblastine (VeIP) or etoposide (VIP) in patients with recurrent germ cell tumors; we also investigated the use of VIP in SCLC. In third-line or greater therapy for recurrent germ cell tumors, a 36% disease-free status was attained, with 16% of patients continuously free of disease for 5 or more years. Currently, ifosfamide is being evaluated as part of initial therapy in patients with advanced disease. In SCLC, VIP has also been investigated as part of initial therapy in patients with extensive disease. The complete response rate of 38% achieved in 37 evaluable patients has spurred the Hoosier Oncology Group to compare the VIP regimen to cisplatin/etoposide in patients with extensive-disease SCLC. Ifosfamide has the broad range of clinical activity, but its ultimate role as part of initial therapy remains to be discerned.

Original languageEnglish
Pages (from-to)35-39
Number of pages5
JournalSeminars in Oncology
Volume19
Issue number1 SUPPL. 1
StatePublished - 1992

Fingerprint

Ifosfamide
Small Cell Lung Carcinoma
Clinical Trials
Etoposide
Cisplatin
Germ Cell and Embryonal Neoplasms
Vinblastine
Testicular Neoplasms
Therapeutics
Pancreatic Neoplasms
Neoplasms

ASJC Scopus subject areas

  • Oncology

Cite this

Clinical trials with ifosfamide : The Indiana University experience. / Loehrer, Patrick; Williams, Stephen D.; Nichols, Craig R.; Einhorn, Lawrence.

In: Seminars in Oncology, Vol. 19, No. 1 SUPPL. 1, 1992, p. 35-39.

Research output: Contribution to journalArticle

Loehrer, P, Williams, SD, Nichols, CR & Einhorn, L 1992, 'Clinical trials with ifosfamide: The Indiana University experience', Seminars in Oncology, vol. 19, no. 1 SUPPL. 1, pp. 35-39.
Loehrer, Patrick ; Williams, Stephen D. ; Nichols, Craig R. ; Einhorn, Lawrence. / Clinical trials with ifosfamide : The Indiana University experience. In: Seminars in Oncology. 1992 ; Vol. 19, No. 1 SUPPL. 1. pp. 35-39.
@article{7b8dcb346e1d4ca9bb0133b8a1a8d91a,
title = "Clinical trials with ifosfamide: The Indiana University experience",
abstract = "At Indiana University, we began clinical trials with ifosfamide in 1981. Although our initial efforts were in a variety of tumor types, including pancreatic cancer, we have most recently focused our attention on two tumors that have historically exhibited a higher degree of chemosensitivity-testicular cancer and small cell lung cancer (SCLC). In phase II trials, ifosfamide has proven to have single-agent activity in both diseases. Coupling this data with preclinical observations of synergy with cisplatin and etoposide, we began trials of ifosfamide plus cisplatin with either vinblastine (VeIP) or etoposide (VIP) in patients with recurrent germ cell tumors; we also investigated the use of VIP in SCLC. In third-line or greater therapy for recurrent germ cell tumors, a 36{\%} disease-free status was attained, with 16{\%} of patients continuously free of disease for 5 or more years. Currently, ifosfamide is being evaluated as part of initial therapy in patients with advanced disease. In SCLC, VIP has also been investigated as part of initial therapy in patients with extensive disease. The complete response rate of 38{\%} achieved in 37 evaluable patients has spurred the Hoosier Oncology Group to compare the VIP regimen to cisplatin/etoposide in patients with extensive-disease SCLC. Ifosfamide has the broad range of clinical activity, but its ultimate role as part of initial therapy remains to be discerned.",
author = "Patrick Loehrer and Williams, {Stephen D.} and Nichols, {Craig R.} and Lawrence Einhorn",
year = "1992",
language = "English",
volume = "19",
pages = "35--39",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "1 SUPPL. 1",

}

TY - JOUR

T1 - Clinical trials with ifosfamide

T2 - The Indiana University experience

AU - Loehrer, Patrick

AU - Williams, Stephen D.

AU - Nichols, Craig R.

AU - Einhorn, Lawrence

PY - 1992

Y1 - 1992

N2 - At Indiana University, we began clinical trials with ifosfamide in 1981. Although our initial efforts were in a variety of tumor types, including pancreatic cancer, we have most recently focused our attention on two tumors that have historically exhibited a higher degree of chemosensitivity-testicular cancer and small cell lung cancer (SCLC). In phase II trials, ifosfamide has proven to have single-agent activity in both diseases. Coupling this data with preclinical observations of synergy with cisplatin and etoposide, we began trials of ifosfamide plus cisplatin with either vinblastine (VeIP) or etoposide (VIP) in patients with recurrent germ cell tumors; we also investigated the use of VIP in SCLC. In third-line or greater therapy for recurrent germ cell tumors, a 36% disease-free status was attained, with 16% of patients continuously free of disease for 5 or more years. Currently, ifosfamide is being evaluated as part of initial therapy in patients with advanced disease. In SCLC, VIP has also been investigated as part of initial therapy in patients with extensive disease. The complete response rate of 38% achieved in 37 evaluable patients has spurred the Hoosier Oncology Group to compare the VIP regimen to cisplatin/etoposide in patients with extensive-disease SCLC. Ifosfamide has the broad range of clinical activity, but its ultimate role as part of initial therapy remains to be discerned.

AB - At Indiana University, we began clinical trials with ifosfamide in 1981. Although our initial efforts were in a variety of tumor types, including pancreatic cancer, we have most recently focused our attention on two tumors that have historically exhibited a higher degree of chemosensitivity-testicular cancer and small cell lung cancer (SCLC). In phase II trials, ifosfamide has proven to have single-agent activity in both diseases. Coupling this data with preclinical observations of synergy with cisplatin and etoposide, we began trials of ifosfamide plus cisplatin with either vinblastine (VeIP) or etoposide (VIP) in patients with recurrent germ cell tumors; we also investigated the use of VIP in SCLC. In third-line or greater therapy for recurrent germ cell tumors, a 36% disease-free status was attained, with 16% of patients continuously free of disease for 5 or more years. Currently, ifosfamide is being evaluated as part of initial therapy in patients with advanced disease. In SCLC, VIP has also been investigated as part of initial therapy in patients with extensive disease. The complete response rate of 38% achieved in 37 evaluable patients has spurred the Hoosier Oncology Group to compare the VIP regimen to cisplatin/etoposide in patients with extensive-disease SCLC. Ifosfamide has the broad range of clinical activity, but its ultimate role as part of initial therapy remains to be discerned.

UR - http://www.scopus.com/inward/record.url?scp=0026817397&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026817397&partnerID=8YFLogxK

M3 - Article

VL - 19

SP - 35

EP - 39

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 1 SUPPL. 1

ER -